Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

Related Articles by Review for PubMed (Select 12350486)

1.

Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.

Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, Humphrey PA, Roehl KA, Catalona WJ.

Urology. 2002 Sep;60(3):469-73; discussion 473-4.

PMID:
12350486
2.

Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.

Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB.

J Urol. 1998 Dec;160(6 Pt 2):2407-11. Review.

PMID:
9817393
4.

Prostate biopsy: who, how and when. An update.

Djavan B, Milani S, Remzi M.

Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100. Review.

PMID:
15780165
5.

Prospective evaluation of men with stage T1C adenocarcinoma of the prostate.

Carter HB, Sauvageot J, Walsh PC, Epstein JI.

J Urol. 1997 Jun;157(6):2206-9. Review.

6.

Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening.

Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ.

J Urol. 1996 Mar;155(3):816-20. Review.

PMID:
8583583
7.

Characteristics of prostate cancer found with early detection regimens.

Brendler CB.

Urology. 1995 Sep;46(3 Suppl A):71-6. Review.

PMID:
7544517
8.

The use of percent free prostate specific antigen for staging clinically localized prostate cancer.

Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW.

J Urol. 1998 Apr;159(4):1238-42. Review.

PMID:
9507844
9.

DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer.

Badalament RA, O'Toole RV, Young DC, Drago JR.

Cancer. 1991 Jun 15;67(12):3014-23. Review.

PMID:
1710533
10.

Should men with serum prostate-specific antigen < or =4 ng/ml and normal digital rectal examination undergo a prostate biopsy? A literature review.

Pepe P, Panella P, D'Arrigo L, Savoca F, Pennisi M, Aragona F.

Oncology. 2006;70(2):81-9. Epub 2006 Apr 4. Review.

PMID:
16601365
11.
12.

Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant.

Bassler TJ Jr, Orozco R, Bassler IC, O'Dowd GJ, Stamey TA.

Urology. 1998 Dec;52(6):1064-9. Review.

PMID:
9836555
13.

[Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma].

Recker F.

Schweiz Med Wochenschr. 1996 Nov 2;126(44):1881-90. Review. German.

PMID:
8984601
14.

Stage T1c prostate cancer: perspectives on clinical management.

Smith JA Jr.

Semin Urol Oncol. 1995 Aug;13(3):238-44. Review.

PMID:
8521137
15.

The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study.

Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkels WJ, Schröder FH.

J Urol. 1999 Apr;161(4):1192-8. Review.

PMID:
10081868
16.

[Characteristics of screening-detected prostate cancer on health checkup].

Uchida K, Akaza H.

Gan To Kagaku Ryoho. 1998 Aug;25(10):1527-32. Review. Japanese.

PMID:
9725044
17.

Staging prostate cancer--1997: current methods and limitations.

Bostwick DG.

Eur Urol. 1997;32 Suppl 3:2-14. Review.

PMID:
9267781
18.

Treatment of stage A1 prostate cancer: the case for observation.

Austenfeld MS.

Semin Urol. 1993 May;11(2):58-63. Review.

PMID:
7689740
19.

The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy.

Moul JW, Kane CJ, Malkowicz SB.

Urol Clin North Am. 2001 Aug;28(3):459-72. Review.

PMID:
11590806
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk